Conteduca, V.; Casadei, C.; Scarpi, E.; Brighi, N.; Schepisi, G.; Lolli, C.; Gurioli, G.; Toma, I.; Poti, G.; Farolfi, A.;
et al. Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Cancers 2022, 14, 2219.
https://doi.org/10.3390/cancers14092219
AMA Style
Conteduca V, Casadei C, Scarpi E, Brighi N, Schepisi G, Lolli C, Gurioli G, Toma I, Poti G, Farolfi A,
et al. Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Cancers. 2022; 14(9):2219.
https://doi.org/10.3390/cancers14092219
Chicago/Turabian Style
Conteduca, Vincenza, Chiara Casadei, Emanuela Scarpi, Nicole Brighi, Giuseppe Schepisi, Cristian Lolli, Giorgia Gurioli, Ilaria Toma, Giulia Poti, Alberto Farolfi,
and et al. 2022. "Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide" Cancers 14, no. 9: 2219.
https://doi.org/10.3390/cancers14092219
APA Style
Conteduca, V., Casadei, C., Scarpi, E., Brighi, N., Schepisi, G., Lolli, C., Gurioli, G., Toma, I., Poti, G., Farolfi, A., & De Giorgi, U.
(2022). Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Cancers, 14(9), 2219.
https://doi.org/10.3390/cancers14092219
